Last updated: February 15, 2026
What is the drug associated with NDC 00121-0773?
NDC 00121-0773 is a medication manufactured by Bristol-Myers Squibb, identified as Orencia (abatacept) injection. It is used primarily to treat rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis. The drug belongs to the biologic DMARD class, targeting T-cell activation pathways.
What is the current market landscape for Orencia (abatacept)?
Market Size (2022):
The global rheumatoid arthritis biologics market was valued at approximately USD 38 billion in 2022, with Orencia accounting for an estimated 8% market share based on sales data[^1].
United States Market:
Orencia's U.S. sales crossed USD 1.2 billion in 2022, placing it among leading biologics for rheumatic diseases. The drug’s market share is driven by:
- Patent exclusivity through 2029,
- Extensive clinical data,
- Prescriber familiarity.
Competitive Dynamics:
Orencia faces competition from agents such as Humira (adalimumab,AbbVie), Enbrel (etanercept, Amgen), and Simponi (golimumab, Janssen). Its market position is challenged primarily by TNF inhibitors, though Orencia's distinct mechanism appeals to patients intolerant to TNF-blockers.
What are the regulatory and patent considerations?
Patent Status:
Bristol-Myers Squibb holds patents extending into late 2029. A biosimilar entry is expected by 2030, based on patent expiry timelines informed by legal filings[^2].
Regulatory Pathways & Approvals:
Orencia is approved by the FDA (since 2005). Biosimilar applications are pending or have received approval in Europe, potentially impacting pricing and market share long-term.
What are the key pricing trends and projections?
Current Pricing (U.S.):
The average wholesale price (AWP) for a single 125 mg dose is approximately USD 3,180. The typical treatment regimen involves 125 mg weekly, leading to annual costs around USD 165,000 per patient.
Pricing Dynamics:
- Post-Patent Expiry:
Biosimilars are expected to enter the US market in 2030, with initial price reductions of 15-25%, similar to trends observed with Humira biosimilars, which saw prices decline by approximately 70%[^3].
- Market Competition:
Biosimilar competition may result in further downward pressure, with projected prices falling to USD 1,200–1,800 per dose within five years of biosimilar launch.
| Projected Price Trajectory (2024–2034): |
Year |
Approximate Price per Dose |
Comments |
| 2024 |
USD 3,150 |
Current price; no biosimilar competition yet |
| 2026 |
USD 2,900–3,050 |
Market begins to feel biosimilar influence |
| 2030 |
USD 1,200–1,500 |
Biosimilar entry; potential price reductions commence |
| 2032 |
USD 1,000–1,200 |
Increased biosimilar competition |
| 2034 |
USD 800–1,000 |
Price stabilization at lower levels |
What factors influence future market and pricing?
-
Patent Litigation and Litigation Outcomes:
Patent disputes could delay biosimilar entry, preserving current pricing levels.
-
Regulatory Approvals:
Successful approval and uptake of biosimilars in the U.S. and globally influence price reductions.
-
Market Penetration of Biosimilars:
Launch strategies, payer policies, and physician acceptance determine biosimilar adoption rates.
-
Healthcare Policy Changes:
Policies favoring biosimilar utilization could accelerate price declines.
Summary of Key Data Points
| Aspect |
Data/Forecast |
| Current market valuation |
USD 1.2 billion (U.S., 2022) |
| Price per dose |
USD 3,180 (approximate) |
| Patent expiry |
2029 (U.S.) |
| Biosimilar launch expected |
2030 |
| Potential biosimilar discount |
70% reduction over current price |
Key Takeaways
- NDC 00121-0773 corresponds to Orencia (abatacept), a critical biologic in rheumatology with USD 1.2 billion U.S. sales in 2022.
- The patent extending into 2029 limits biosimilar competition until then. Biosimilars could enter the market around 2030.
- Prices are projected to decline significantly upon biosimilar entry, with potential reductions reaching 70%, bringing the post-biosimilar price per dose below USD 1,000.
- Market share will depend on biosimilar acceptance, physician prescribing habits, and regulatory developments.
FAQs
1. When will biosimilars for abatacept enter the U.S. market?
Expected around 2030, aligning with patent expiry.
2. How much could biosimilar drugs reduce the price of Orencia?
Potentially by up to 70%, decreasing the annual treatment cost from approximately USD 165,000 to below USD 50,000 per patient.
3. What are the main competitors to Orencia?
TNF inhibitors like Humira, Enbrel, and Simponi.
4. How does patent litigation impact biosimilar entry?
Legal disputes can delay market entry, prolonging higher prices.
5. What factors could accelerate biosimilar adoption?
Regulatory approval, policy incentives, payer coverage, and physician acceptance.
Sources
[1] EvaluatePharma, 2022. Global RA biologic market valuation.
[2] FDA Patent Data, 2023. Patents related to abatacept.
[3] IQVIA, 2022. Biologics market trends and biosimilar impact.
